Assistant Professor Pharmacy Practice Department Definition Hyperlipidemia hyperlipoproteinemia or hyperlipidaemia involves abnormally elevated levels of any or all lipids andor lipoproteins in the ID: 779384
Download The PPT/PDF document "HYPERLIPIDAEMIAS Dr.D.Rispa" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
HYPERLIPIDAEMIAS
Dr.D.RispaAssistant ProfessorPharmacy Practice Department
Slide2Definition
Hyperlipidemia, hyperlipoproteinemia, or hyperlipidaemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood.It is the most common form of dyslipidemia (which also includes any decreased lipid levels).
Slide3Lipoproteins
A lipoprotein is a biochemical assembly that contains both proteins and lipids, bound to the proteins, which allow fats to move through the water inside and outside cells.The proteins serve to emulsify the lipid (otherwise called fat) molecules. Many enzymes, transporters, structural proteins, antigens, adhesins, and toxins are lipoproteins.Examples include the high-density (HDL) and low-density (LDL) lipoproteins, which enable fats to be carried in the blood
stream.
Slide4Types of Lipoproteins
Density (g/ml)
ClassDiameter (nm)%protein
%
Cholesterol
%
Phospholoipd
%
triglycerol
& cholesterol ester
>1.063
HDL
5-15
33
30
29
4
1.019-1.063
LDL
18-28
25
50
21
8
1.006-1.019
IDL
25-50
18
29
22
31
0.95-1.006
VLDL
30-80
10
22
18
50
<0.95
Chylomicrons
100-1000
<2
8
7
84
Slide5Chylomicrons carry triglycerides (fat) from the intestines to the liver, to skeletal muscle, and to adipose tissue.
Very-low-density lipoproteins (VLDL) carry (newly synthesised) triglycerides from the liver to adipose tissue. Intermediate-density lipoproteins (IDL) are intermediate between VLDL and LDL. They are not usually detectable in the blood. Low-density lipoproteins (LDL) carry cholesterol from the liver to cells of the body. LDLs are sometimes referred to as the "bad cholesterol" lipoprotein. High-density lipoproteins (HDL) collect cholesterol from the body's tissues, and take it back to the liver. HDLs are sometimes referred to as the "good cholesterol" lipoprotein.
Slide6Classifcation
Slide7Relative prevalence of familial Hyperlipoproteinemias
Slide8Hyperlipoproteinemia type I
Type I hyperlipoproteinemia exists in several forms: Lipoprotein lipase deficiency (Type Ia), due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein
C2, resulting in elevated chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver. Familial apoprotein CII deficiency (Type Ib), a condition caused by a lack of lipoprotein lipase activator
.
Chylomicronemia
due to circulating inhibitor of lipoprotein lipase (Type
Ic
)
Type I
hyperlipoproteinemia
usually presents in childhood with eruptive
xanthomata
and abdominal colic. Complications include retinal vein occlusion, acute pancreatitis,
steatosis
and
organomegaly
, and
lipaemia
retinalis
.
Slide9Hyperlipoproteinemia type II
Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol
.Type II (a)This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the LDL receptor gene on chromosome 19 (0.2% of the population) or the ApoB
gene (0.2%). The familial form is characterized by tendon
xanthoma
,
xanthelasma
and premature cardiovascular disease. The incidence of this disease is about 1 in 500 for heterozygotes, and 1 in 1,000,000 for homozygotes
.
Type II (b)
The
high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.
Familial combined
hyperlipoproteinemia
(FCH)
Lysosomal
acid lipase deficiency, often called (
Cholesteryl
ester storage disease)
Secondary combined
hyperlipoproteinemia
(usually in the context of metabolic syndrome, for which it is a diagnostic criterion)
Slide10Hyperlipoproteinemia
type IIIThis form is due to high chylomicrons and IDL (intermediate density lipoprotein). Also known as broad beta disease or dysbetalipoproteinemia, the most common cause for this form is the presence of ApoE E2/E2 genotype. It is due to cholesterol-rich VLDL (β-
VLDL). Its prevalence has been estimated to be approximately 1 in 10,000.Hyperlipoproteinemia
type
IV
Familial hypertriglyceridemia is an autosomal recessive condition occurring in approximately 1% of the population
.
Hyperlipoproteinemia
type
V
Hyperlipoproteinemia
type V is very similar to type I, but with high VLDL in addition to chylomicrons
.
It is also associated with glucose intolerance and
hyperuricemia
.
Slide11Acquired (secondary)
Acquired hyperlipidemias (also called secondary dyslipoproteinemias) often mimic primary forms of hyperlipidemia and can have similar consequences. They may result in increased risk of premature atherosclerosis or, when associated with marked hypertriglyceridemia, may lead to pancreatitis and other complications of the
chylomicronemia syndrome. The most common causes of acquired hyperlipidemia are:
diabetes
mellitus
Use of drugs such as diuretics
, beta
blockers
,
and
estrogens
Other conditions leading to acquired hyperlipidemia include:
Hypothyroidism
renal
failure
nephrotic
syndrome
alcohol
usage
Some rare endocrine
disorders
and metabolic
disorders
.
Slide12Epidemiology
Lipid and lipoprotein concentrations vary among different populations with countries consuming a western type of diet having higher TC and LDL levels than those where regular consumption of saturated fat is low.Despite a 50% reduction in the death rate from CVD over the past 25 years, It remains the leading cause of premature death and morbidity in the UK.The higher levels of TC in an individual the greater the chance of developing CVD.TC levels tend to increase with age such that 80% of British men aged 45-64 years have a level that exceeds 5mmol/lit and the population average is 5.6
mmol/lit, in contrast in rural China and Japan the average is 4 mmol/lit.
Slide13Etiology
The etiology can be classified into primary and secondary causes.Primary causes are due to single or multiple gene mutations resulting in a disturbance of LDL and triglyceride production or clearance.They vary in location of genetic defect, inheritance pattern, prevalence, clinical features, and treatment.
At least 18 separate entities have been described. The suspicion for a primary lipid disorder should be especially high in patients with premature atherosclerotic disease, a family history of early atherosclerotic disease, a significantly elevated serum cholesterol level (>240 mg/dL), and physical signs of hyperlipidemia
.
Primary
dyslipidemias are most commonly seen in children and young adults and cause only a small percentage of cases in adults.
Slide14Most adult cases of dyslipidemia are secondary in nature.
In Western civilizations, sedentary lifestyle and excessive consumption of saturated fats, trans-fatty acids, and cholesterol are the most important secondary causes.Certain medical conditions are commonly associated with dyslipidemia, including chronic renal insufficiency, renal failure, diabetes mellitus, hypothyroidism, cholestatic liver disease, and alcohol dependency.Certain
drugs, including high-dose thiazide diuretics, oral estrogens, glucocorticoids, anabolic steroids, and atypical antipsychotics such as olanzapine and clozapine have also been implicated in causing mild-to-moderate degrees of dyslipidemia.Use of atypical antipsychotics, such as olanzapine and clozapine, and of beta-blockers without intrinsic sympathomimetic or alpha-blocking activities are associated with reduced HDL-cholesterol
levels.
Slide15Pathophysiology
Hypercholesterolemia develops as a consequence of abnormal lipoprotein metabolism, mainly reduction of LDL receptor expression or activity, and consequently diminishing hepatic LDL clearance from the plasma.It is a major predisposing risk factor for the development of atherosclerosis.This mechanism is classically seen in familial hypercholesterolemia and when excess saturated fat or cholesterol is
ingested.In addition, excessive production of VLDL by the liver, as seen in familial combined hyperlipidemia and insulin resistance states such as abdominal obesity and type 2 diabetes, can also induce hypercholesterolemia or mixed dyslipidemia.
Slide16Pathways
Slide17A current theory for the initiating event in atherogenesis
is that apoprotein B-100-containing lipoproteins are retained in the subendothelial space, by means of a charge-mediated interaction with extracellular matrix and proteoglycans.This allows reactive oxygen species to modify the surface phospholipids and unesterified cholesterol of the small LDL particles.
Circulating LDL can also be taken up into macrophages through unregulated scavenger receptors.As a result of LDL oxidation, isoprostanes are formed.
Isoprostanes
are chemically stable, free radical-catalyzed products of
arachidonic
acid, and are structural isomers of conventional
prostaglandins.
Isoprostane
levels are increased in atherosclerotic lesions, but they may also be found as F2
isoprostanes
in the urine of asymptomatic patients with hypercholesterolemia.
Slide18A strong association exists between elevated plasma concentrations of oxidized LDL and
CHD.The mechanisms through which oxidized LDL promotes atherosclerosis are multiple and include damage to the endothelium, induction of growth factors, and recruitment of macrophages and monocytes.Vasoconstriction in the setting of high levels of oxidized LDL seem to be related to a reduced release of the vasodilator nitric oxide from the damaged endothelial wall as well as increased platelet aggregation and thromboxane release.Smooth muscle proliferation has been linked to the release of cytokines from activated platelets
.The state of hypercholesterolemia leads invariably to an excess accumulation of oxidized LDL within the macrophages, thereby transforming them into "foam" cells. The rupture of these cells can lead to further damage of the vessel wall due to the release of oxygen free radicals, oxidized LDL, and intracellular enzymes.
Slide19Symptoms
Hyperlipidemia usually does not cause symptoms. Very high levels of lipids or triglycerides can cause: Fat deposits in the skin or tendons ( Xanthelasma and
Xanthoma ) Pain, enlargement, or swelling of organs such as the liver, spleen, or pancreas ( Pancreatitis ) Obstruction
of blood vessels in heart and brain
If not treated, high lipids can cause:
Heart
Attack
Stroke
Atherosclerosis
(hardening of the arteries)
Slide20Slide21Diagnosis
This condition is diagnosed with blood tests.These tests measure the levels of lipids in the blood.
The National Cholesterol Education Program advises that you have your lipids checked at least once every five years, starting at age 20.Also, the American Academy of Pediatrics recommends lipid screening for children at risk (
eg
, a family history of hyperlipidemia).
Testing may consist of a fasting blood test for:
Total cholesterol
LDL (bad cholesterol)
HDL (good cholesterol)
Triglycerides
Your doctor may recommend more frequent or earlier testing if you have:
Family history of
hyperlipidemia.
Risk factor or disease that may cause
hyperlipidemia.
Complication that may result from
hyperlipidemia.
Slide22Slide23Treatment
Non Pharmacologic:Diet, lifestyle changes, and medication can help treat hyperlipidemia.Diet ChangesEat a diet low in total fat, saturated fat, and cholesterol.
Reduce or eliminate the amount of alcohol you drink.Eat more high-fiber foods. Lifestyle ChangesIf you are overweight, lose weight.
If you smoke, quit.
Exercise
regularly.
Talk
to you doctor before starting an exercise
program.
You
may already have hardening of the arteries or heart disease
.
These
conditions increase your risk of having a heart attack while exercising
.
Slide24Pharmacological:
Classfication:HMG CoA Reductase Inhibitors (statins):Lovastatin, Simvastatin, AtorvastatinBile acid sequesterants
:Cholestyramine, ColestipolActivated lipo
protein lipase (
fibric
acid derivatives):
Gemfibrozil
,
Clofibrate
,
Fenofibrate
Inhibit lipolysis and TG synthesis:
Nicotinic acid
Others:
Ezetimibe
,
Gugulipid
Slide25Slide26Statins(Atorvastatin, Lovastatin)
Dose-AtorvastatinInital: 10 or 20 mg once daily, may increase slowly if needed. Max: 80 mg/day.
LovastatinInitial: 10-20 mg/day at bedtime, may increase 4-wkly if needed. Max: 80 mg/day (immediate-release)
Adverse Effects:
Gastrointestinal
:
Diarrhea (up to 14.1% )
Musculoskeletal
:
Arthralgia (up to 11.7% ), Myalgia (up to 8.4% )
Renal
:
Urinary tract infectious disease (up to 8% )
Respiratory
:
Nasopharyngitis
(8.3% )
Other
:
Pain, In extremity (up to 9.3%
)
Dermatologic
:
Dermatomyositis
Hepatic
:
Increased liver enzymes (0.2% to 2.3% ), Liver failure
Immunologic
:
Autoimmune disease, Systemic lupus
erythematosus
Musculoskeletal
:
Disorder of muscle,
Rhabdomyolysis
, Rupture of
tendon.
Slide27Gemfibrozil
Dose: 1.2 g/day in 2 divided doses. Maintenance: 0.9-1.5 g/dayGastrointestinal: Abdominal pain (9.8% ), Acute appendicitis (1.2% ), Indigestion (19.6% .)
Hepatic: Increased liver functionMusculoskeletal: Rhabdomyolysis
Slide28Clofibrate
Dose: 2 g/day in divided doses.Cardiovascular
EffectsCardiac dysrhythmiaCardiomyopathyCardiovascular finding
Thrombophlebitis
Dermatologic Effects
Dermatological finding
Stevens-Johnson syndrome
Endocrine/Metabolic Effects
Endocrine finding
Increased body temperature
Metabolic finding
Weight
gain
Slide29Bile acid sequesterants(
Cholestyramine, Colestipol)Dose: 5 g 1-2 times/day, up to 30 g/day if needed
Gastrointestinal: Abdominal discomfort, Constipation, Flatulence, Nausea and vomiting
Slide30Niacin
Dermatologic: Flushing (88% )Gastrointestinal: Nausea (4% to 9% ), Vomiting (2% to 9% )Hepatic: Hepatic necrosis, HepatotoxicityMusculoskeletal: Rhabdomyolysis
Slide31Gugulipid
diarrheanauseahiccupabdominal discomfortheadacherestlessness hypersensitivity rash
Slide32THANK YOU